CNBC

24 Oct 2026, 18:56 UTC · 1h ago

Biotech stocks are surging. How investors can play the new drug innovation boom

Impact · against what's priced in

The article provides no meaningful catalysts for the listed biotech names, as the positive clinical updates for Eli Lilly and Roche are already factored into their current valuations. Most of the news serves as confirmation of existing growth trajectories and pipeline expectations.

LLY+0.10: Challenges what's priced in
The price assumes: The next-generation pipeline, specifically retatrutide's potential for superior weight loss

How each ticker is affected

TXG+0.90

More positive than 97% of ticker scores this week

Stock up more than 300% with its Atera platform helping accelerate personalized therapies via AI.

ILMN+0.90

More positive than 97% of ticker scores this week

Stock has more than doubled due to accelerating demand for its NovaSeq X platform.

LLY+0.80

More positive than 90% of ticker scores this week

Positive clinical trial results for its next-generation obesity drug retatrutide showing significant weight loss.

RHHBY+0.80

More positive than 90% of ticker scores this week

Received FDA approval for its drug Enspryng for thyroid eye disease.

AZN+0.70

More positive than 84% of ticker scores this week

Released positive Phase 3 results for the drug Tezspire for throat inflammation.

MRK+0.70

More positive than 84% of ticker scores this week

Positive outcomes for its melanoma drug in conjunction with Moderna and collaboration on precision oncology.

AMGN+0.70

More positive than 84% of ticker scores this week

Released positive Phase 3 results for the drug Tezspire for throat inflammation.

MRNA+0.60

More positive than 78% of ticker scores this week

Despite a temporary stock dip, the company has seen a massive YTD surge and has promising mRNA cancer vaccine data.

BMY+0.30

More positive than 61% of ticker scores this week

Mentioned as working with Illumina to develop precision oncology solutions.

KURA+0.30

More positive than 61% of ticker scores this week

Mentioned as working with Illumina to develop precision oncology solutions.

PFE+0.00

Near neutral — 91% of ticker scores this week are stronger

Mentioned only in the context of historical performance during the Covid era.

BNTX+0.00

Near neutral — 91% of ticker scores this week are stronger

Mentioned only in the context of historical performance during the Covid era.

Biotech stocks are surging. How investors can play the new drug innovation boom

What matters in this story

Alibaba vs. Booking: Which Travel Provider Stock Is a Better Buy in 2026?

Biotech stocks are surging. How investors can play the new drug innovation boom

What matters in this story

Alibaba vs. Booking: Which Travel Provider Stock Is a Better Buy in 2026?

How each ticker is affected

Connected tickers

Track these names every morning.

Adobe: A Fairly Priced Compounder In An Expensive Market

Peter Thiel says Apple has done 'nothing new' after Steve Jobs

SK hynix: Don't Bet On The Slower Boat In A Fast Tide

SpaceX's "Super Intelligence" Segment Just Made the Stock a Must-Own

Biotech stocks are surging. How investors can play the new drug innovation boom

What matters in this story

Next reads from the same story arc

Alibaba vs. Booking: Which Travel Provider Stock Is a Better Buy in 2026?

Biotech stocks are surging. How investors can play the new drug innovation boom

What matters in this story

Next reads from the same story arc

Alibaba vs. Booking: Which Travel Provider Stock Is a Better Buy in 2026?

How each ticker is affected

Connected tickers

Track these names every morning.

Adobe: A Fairly Priced Compounder In An Expensive Market

Peter Thiel says Apple has done 'nothing new' after Steve Jobs

SK hynix: Don't Bet On The Slower Boat In A Fast Tide

SpaceX's "Super Intelligence" Segment Just Made the Stock a Must-Own